Talking Medicines targets messaging risk in pharma brand strategy

Tern plc

Pharma teams typically begin with a clear brand narrative built on scientific evidence. But as this narrative moves through marketing, compliance and external agencies, the original message can become diluted. When that happens, healthcare professionals may misinterpret or disengage from the brand. The result is weaker positioning, lower impact and reduced return on marketing investment.

Talking Medicines addresses this problem by offering real-time analytics that measure how healthcare professionals actually receive and interpret brand messages. Instead of waiting for post-campaign reports, teams can see early signals of what is working and adjust strategy before value is lost. This is especially relevant during launch phases, where the ability to course-correct quickly can have a material impact on performance.

Its DrugVoice platform captures unstructured HCP dialogue and turns it into structured insight. This data helps brand teams understand whether their messages are understood, aligned with clinical priorities and prompting the right actions. For leadership, it offers a way to verify that brand strategy is being delivered as intended.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search